STAT+: Drug company penalties for paying kickbacks to doctors failed to dent bottom lines, analysis finds
Pharmaceutical companies caught paying doctors to prescribe their drugs have paid roughly two cents in penalties for every dollar of revenue generated by the drugs involved in those schemes over the past quarter century. That is not a deterrent. It is a licensing fee.
A study published last month in JAMA Network Open by Tobias Liu and colleagues analyzed 64 Anti-Kickback Statute (AKS) cases involving drugmakers between 2020 and 2025, finding complete financial data in 46 of them. The conclusion: companies paid just 2.2 percent of U.S. revenue from the implicated drugs as penalties across the 25-year study window. The study, titled "Pharmaceutical Manufacturer Kickback Resolutions and Associated Financial Penalties, 2000-2025," was published March 2026 (PMID 41823969) and drew on government settlement records.
The finding fits a long pattern. Public Citizen, the consumer advocacy group, has tracked pharma penalties since 1991 and documented $62.3 billion in settlements across 482 cases through 2021. Yet fines keep coming, and the same companies keep appearing. Pfizer tops the recidivism list with 15 settled cases, followed by Novartis with 12, GlaxoSmithKline with 9, and Bristol Myers Squibb with 9, according to Public Citizen's settlement database. GSK alone paid nearly $10 billion in inflation-adjusted penalties between 2003 and 2016, the highest tally of any drugmaker in that window, per a separate analysis published via EurekAlert. None of them stopped.
The mechanism is not complicated. A company weighs the probability of getting caught, the size of the penalty if caught, and the revenue generated by the scheme. When those numbers favor the scheme, companies run the scheme. "Pharma fines increase, but the pain is not felt on Wall Street," as a 2013 Nature Medicine paper put it, observing that the market treated GSK's $3 billion 2012 settlement with the U.S. government as a non-event.
Novartis provides a recent data point. The company paid $678 million in 2020 to settle AKS kickback allegations brought by the Justice Department, resolving claims that it paid doctors speaking fees and speaking-adjacent fees to boost sales of certain drugs. Pfizer paid $59.7 million in January 2025 to resolve similar allegations involving its migraine drug Nurtec ODT. Both were large settlements by ordinary standards. Neither approached the revenue those companies generated from the drugs in question.
The Jan. 27, 2026 OIG bulletin adds a new dimension. The Office of Inspector General for the Department of Health and Human Services issued a special advisory that month outlining Anti-Kickback Statute implications for direct-to-consumer drug sales, particularly ahead of the TrumpRx program launch. The bulletin flagged remuneration models in DTC prescription drug channels as an area of heightened enforcement concern. The DTC channel creates fresh opportunities for the same old schemes: copay assistance programs, patient hub services, and referral arrangements that can look like legitimate support and smell like kickbacks.
Physicians who receive industry payments are two to three times more likely to prescribe name-brand drugs over generics or cheaper alternatives, according to research compiled by CaseIQ, a legal analytics firm specializing in pharmaceutical fraud. That is the demand side of the problem. Drugmakers are not paying doctors out of generosity. They are buying prescribing behavior, and the literature consistently shows they are getting it.
A 2018 Yale study found that cardiologists were between two and 11 times more likely to implant a defibrillator made by the device company that paid them the most money. That finding, from Curtis et al. in Circulation: Cardiovascular Quality and Outcomes (PMID 30562077), has not aged out of relevance. The financial relationships shaping device implantation decisions are the same dynamics shaping prescribing decisions.
Some legal scholars argue the answer is qui tam jurisprudence rather than regulatory enforcement. A judgment entered in March 2025 awarded $1.64 billion in an AKS and False Claims Act case, of which $360 million was treble damages and $1.28 billion penalties, per Gibson Dunn's midyear FCA update. The False Claims Act allows whistleblowers, typically former employees, to sue on behalf of the government and share in recoveries. It is a decentralized enforcement mechanism that, in theory, scales with the profitability of misconduct. In practice, cases take years, settlements are often sealed, and the penalties even when collected rarely approach the revenue generated from the underlying conduct.
The JAMA study authors note that AKS violations carry penalties of up to $100,000 per violation and up to 10 years in prison under federal law, and that each violation is treated as a per se violation of the False Claims Act. The statutory maximum sounds serious. The settlement reality is not.
What would actually change behavior? Researchers who study corporate crime argue that enforcement consistency matters more than penalty size. Uncertain detection, not certain punishment, is what drives the calculus. A regulator that catches 100 percent of violators with a modest fine deters more than one that catches 10 percent with a large one. By that standard, the current system is calibrated to fail. The drugs involved in AKS settlements represent a small fraction of total prescribing, and settlements rarely make it into the public record in enough detail to let competitors or investors price the risk.
The JAMA data covers a period before the full rollout of TrumpRx and its DTC implications. The OIG bulletin suggests the enforcement picture is getting more complex, not less. Whether that complexity produces tighter compliance or new gray zones is the question worth watching. The answer will not come from the penalty totals, which will continue to look large in absolute terms and small as a percentage of revenue. It will come from whether detection improves enough to make the economics flip.